Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants — 24 States, December 2024–April 2025
by from Morbidity and Mortality Weekly Report (MMWR) on (#71M4R)
This report describes a multicenter case-control investigation that found nirsevimab was 80% effective at preventing RSV-associated ICU admissions among infants.